Volume 24, Number 2—February 2018
Research
Plasmid-Encoded Transferable mecB-Mediated Methicillin Resistance in Staphylococcus aureus
Karsten Becker
, Sarah van Alen, Evgeny A. Idelevich, Nina Schleimer, Jochen Seggewiß, Alexander Mellmann, Ursula Kaspar, and Georg Peters
, Sarah van Alen, Evgeny A. Idelevich, Nina Schleimer, Jochen Seggewiß, Alexander Mellmann, Ursula Kaspar, and Georg Peters
Table 2
Susceptibility to antimicrobial drugs of Staphylococcus aureus isolate UKM4229 from a 67-year-old cardiology inpatient who had no signs of infection, Münster, Germany*
| Antimicrobial class and agent | Median MIC, µg/mL | Category |
|---|---|---|
| β-lactams | ||
| Penicillins | ||
| Benzylpenicillin | 1.5 | R |
| Ampicillin | 3 | |
| Ampicillin/sulbactam | 2 | |
| Piperacillin | 6 | |
| Piperacillin/tazobactam | 3 | |
| Oxacillin | 12 | |
| Oxacillin† | 4/4 | |
| Cephalosporins | ||
| Cefoxitin | 32 | R |
| Cephalothin | 2 | |
| Cefuroxime | 3 | |
| Ceftriaxone | 24 | |
| Cefepime | 6 | |
| Ceftobiprole | 2 | S |
| Ceftaroline | 0.5 | S |
| Carbapenems | ||
| Imipenem |
0.032 |
|
| Non–β-lactams | ||
| Glycopeptides | ||
| Vancomycin | 1 | S |
| Lipoglycopeptides | ||
| Telavancin | 0.012 | |
| Lipopeptides | ||
| Daptomycin | 0.19 | S |
| Fluoroquinolones | ||
| Levofloxacin | 0.19 | S |
| Macrolides | ||
| Erythromycin | >256 | R |
| Lincosamids | ||
| Clindamycin | >256 | R |
| Oxazolidiones | ||
| Linezolid | 1 | S |
| Rifamycins | ||
| Rifampin | 0.008 | S |
| Phosphonic acid derivatives | ||
| Fosfomycin | <0.064 | S |
| Streptogramins | ||
| Quinupristin/dalfopristin | 0.5 | S |
| Tetracyclines | ||
| Tetracycline | 12 | R |
| Glycylcyclines | ||
| Tigecycline | 0.125 | S |
| Folate pathway inhibitors | ||
| Trimethoprim/sulfamethoxazole | 0.047 | S |
| Aminoglycosides | ||
| Gentamicin | 24 | R |
| Pseudomonic acids | ||
| Mupirocin | 0.19 | S |
| Fusidanes | ||
| Fusidic acid | 0.094 | S |
| Bacteriophage endolysins | ||
| HY-133 | 0.25 |
*Tested by using the gradient diffusion method. S, susceptible; R, resistant (according to EUCAST [www.eucast.org] for antibiotic drugs with available breakpoints)
†Conditions: 2% NaCl, 30°C; 18 h/48 h. MIC at regular reading after 18 ± 2 h/MIC after 48 h.
Page created: January 17, 2018
Page updated: January 17, 2018
Page reviewed: January 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.